Document:

EX-10.8

 Exhibit 10.8 

Execution Copy 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made by and between C4 Therapeutics, Inc. (the “Company”), and
Andrew Hirsch (the “Executive”), and is effective as of this 6th day of September, 2020 (the “Effective Date”). 

WHEREAS, the Company wishes to hire the Executive as an employee, and the Executive wishes to be hired by the Company as an employee, on the
terms set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1.
Employment. 
 (a) Term. The term of this Agreement shall commence on the Effective Date and continue until
terminated in accordance with the provisions hereof (the “Term”). The Executive’s employment with the Company will commence on September 14, 2020 (the “Start Date”) and will be “at will,” meaning that the
Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement. 

(b) Position and Duties. During the Term, the Executive shall initially serve as the President of the Company and, upon
the earlier of (i) the close of business on the first day of trading of the Company’s common stock after the Company’s initial public offering of shares of the Company’s common stock (the “IPO”) and
(ii) November 1, 2020, Executive shall serve as the Chief Executive Officer of the Company. In each case, Executive shall have powers and duties that may from time to time be prescribed by the Board of Directors of the Company (the
“Board”), provided that such duties are consistent with the Executive’s position or other positions that the Executive may hold from time to time. As of the Effective Date, the Executive will also serve as a member of the
Board. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may (i) serve on other boards of directors, with the prior written
approval of the Board, (ii) serve on the board of directors of Editas Medicine, (iii) serve as a consultant to his former employer, Agios Pharmaceuticals, Inc., for no more than 5 hours per week, until October 31, 2020, (iv) serve on
the board of directors of not-for-profit or tax-exempt charitable organizations, (v) engage in religious, charitable or
other community activities, (vi) manage the Executive’s personal, financial and legal affairs, and (vii) participate in trade associations, in each case, as long as such services and activities do not materially interfere with the
Executive’s performance of the Executive’s duties to the Company as provided in this Agreement. 
 2. Compensation and Related
Matters. 
 (a) Base Salary. During the Term, the Executive’s initial base salary rate shall be $560,000 per
annum. The Executive’s base salary may be increased by the Board or the Compensation Committee, provided that the Company may decrease the base salary by no more than 15% solely in connection with an across-the-board salary reduction that is based on the Company’s financial performance and similarly affects all or substantially all senior management employees of the Company . The Executive’s
base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. 

(b) Incentive Compensation. During the Term, the Executive shall be eligible to receive cash incentive compensation as
determined by the Board or the Compensation Committee in its discretion. The Executive’s target annual incentive compensation shall be 55 percent (55%) of the Executive’s Base Salary, as such percentage may be increased from time to
time (the “Target Incentive Compensation”), provided that the Company may decrease by no more than 15% in connection with an across-the-board
target incentive compensation percentage reduction that is based on the Company’s financial performance and similarly affects all or substantially all senior management employees of the Company . The actual

 
amount of the Executive’s annual incentive compensation for any year, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of
any applicable incentive compensation plan that may be in effect from time to time. Annual incentive compensation shall be paid to the Executive no later than March 15 of the year following the year in which it is earned. To earn any annual
incentive compensation, the Executive must be employed by the Company for the entire preceding calendar year. If this Agreement is entered into in connection with the commencement of the Executive’s employment with the Company, the
Executive’s Target Incentive Compensation, if any, for such year shall be prorated depending on when in the year the Executive first date of employment with the Company occurs. 

(c) Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by
the Executive during the Term in performing services hereunder, in accordance with and subject to the policies and procedures then in effect and established by the Company for its executive officers. 

(d) Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the
Company’s employee benefit plans in effect from time to time on a basis no less favorable than other senior management employees of the Company, subject to the terms and conditions of such plans. 

(e) Vacations. The Executive shall be eligible for vacation time in accordance with, and subject to, the Company’s
vacation policy as in effect from time to time. The Executive shall also be entitled to all paid holidays given by the Company to its executives. 

(f) Equity. The Executive will be granted options to purchase shares of the Company’s common stock (the
“Options”) as follows: 
 (i) If the IPO becomes effective before November 1, 2020, the Options: 

(A) Will be for such number of shares as is equal to 3.5% of the Company’s outstanding common stock, calculated on a
Fully Diluted Basis (as defined below), and after giving effect to the grant of such Options and any other options granted on that date; 

(B) Will be granted as of the effective date of the Company’s registration statement for the IPO, with an exercise price
per share equal to the public offering price in the IPO; 
 (C) Will provide that, if the overallotment option is not
ultimately exercised, 15% of the Options shall automatically be forfeited and cancelled; 
 (ii) If the IPO has not become
effective before November 1, 2020, the Executive: 
 (A) Will be granted an initial option on or promptly after such
date for such number of shares as is equal to 3.5% of the Company’s outstanding common stock as of the date of grant, calculated on a Fully Diluted Basis (and after giving effect to the grant of such initial option and any other options granted
on that date), at an exercise price equal to the then fair value of the common stock as of such grant date, as determined by the Board of Directors in accordance with their usual procedures as a private company; 

(B) Upon the later completion of the IPO, the Executive will be granted an additional option for such number of additional
shares as is equal to 3.5% of the shares ultimately issued in the IPO, assuming the exercise of the underwriters’ overallotment option, such grant to be made effective on the effective date of the registration statement for such IPO, at an
exercise price equal to the IPO price, with 15% of such grant being automatically forfeited and cancelled if the overallotment option is not ultimately exercised. 

 (C) The options granted under clauses (A) and (B) of this
Section 2(f)(ii) shall be collectively referred to as the “Options” for purposes of this scenario. 
 (iii)
The Options, regardless of when granted, shall provide for vesting over four years beginning on the Start Date, with the initial 12.5% of the options becoming vested on the six month anniversary of the Start Date and the remainder in equal quarterly
installments thereafter; 
 (iv) For purposes hereof, “Fully Diluted Basis” means all of the outstanding
shares of the Company’s common stock, taking into account and treating as outstanding for this purpose (A) all shares of common stock issuable upon exercise or conversion of all then outstanding convertible securities, options or warrants
(whether vested or unvested) and (B) if determined in connection with an Option grant arising in connection with an IPO, (1) the number of shares of common stock issued by the Company in such offering and (2) the number of shares of
common stock as would be issued by the Company if the banks underwriting the IPO were to exercise their overallotment option or “green shoe” in full. For the avoidance of doubt, the number of shares outstanding on a Fully Diluted Basis
shall not include shares of common stock reserved for issuance under any outstanding equity plan that are available for grant or issuance but are not associated with outstanding awards or grants. 

(v) The equity awards held by the Executive shall be governed by the terms and conditions of the Company’s applicable
equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards held by the Executive (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to
the contrary in the Equity Documents, Section 5(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason, in either event within the Change in Control Period (as such
terms are defined below). 
 (g) Legal Fees. The Company agrees to pay the Executive’s reasonable legal fees incurred in
connection with the negotiation of, and entry into, this Agreement, up to a maximum of ten thousand dollars ($10,000). The Company will pay such legal fees within thirty (30) days following receipt of an invoice establishing such fees which
invoice shall be provided by the Executive to the Company promptly following the Start Date. 
 3. Termination. During the Term, the
Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances: 

(a) Death. The Executive’s employment hereunder shall terminate upon the Executive’s death. 

(b) Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to
perform or expected to be able to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in
any 12-month period. If any question shall arise as to whether, during any period, the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position
or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the
Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall, for the purposes of this Agreement, be deemed to be conclusive of the
issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including,
without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 

 (c) Termination by Company for Cause. The Company may terminate the
Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) conduct by the Executive constituting a material act of misconduct in connection with the performance of the
Executive’s duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal
purposes; (ii) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any conduct by the Executive that would reasonably be expected to result in material economic injury or
material reputational harm to the Company or any of its subsidiaries and affiliates if the Executive were retained in the Executive’s position; (iii) willful and intentional continued non-performance
by the Executive of the Executive’s duties hereunder (other than by reason of the Executive’s physical or mental illness, incapacity or disability) that has continued for more than 30 days following written notice from the Board of such
willful and intentional continued non-performance from the Board or the CEO, as applicable; (iv) a material breach by the Executive of any of the provisions contained in Section 7 of this Agreement
or of the Restrictive Covenants Agreement; (v) a material violation by the Executive of the Company’s written employment or corporate governance policies; or (vi) the failure to reasonably cooperate with a bona fide internal
investigation or an investigation by regulatory or law enforcement authorities after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such
investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. 

(d) Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without
Cause. Any termination by the Company of the Executive’s employment under this Agreement that does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under
Section 3(a) or (b) shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The
Executive may terminate the Executive’s employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with
the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events without the Executive’s consent: (i) a material diminution in the Executive’s responsibilities, authority or
duties; (ii) a diminution in the Executive’s Base Salary, except for across-the-board salary and/or target incentive compensation percentage reductions of no
more than 15% that, in either case, are based on the Company’s financial performance and similarly affect all or substantially all senior management employees of the Company; (iii) a requirement that the Executive work primarily from an
office that is more than 30 miles from the office that the Executive primarily provides services to the Company; (iv) the removal of the Executive as the Company’s Chief Executive Officer (or the failure of the Company to appoint the
Executive as Chief Executive Officer of the Company); (v) the removal of the Executive as a member of the Board; or (vi) the Company’s breach of any material provision this Agreement or any other agreement between the Executive and the
Company or any of its subsidiaries. “Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a Good Reason condition has occurred; (ii) the Executive notifies the Company in writing
of the first occurrence of the Good Reason condition within 90 days of the date on which the Executive first became aware of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less
than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates the Executive’s
employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

(f) Notice of Termination. Except for termination as specified in Section 3(a), any termination of the
Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall
mean a notice that shall indicate the specific termination provision in this Agreement being relied upon. 

 (g) Date of Termination. “Date of Termination” shall
mean: (i) if the Executive’s employment is terminated by the Executive’s death, the date of the Executive’s death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by
the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given
unless another date is specified by the Company; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given; and
(v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, if the Executive
gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 

(h) Resignations. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board
member positions that the Executive holds with the Company or any of its subsidiaries or controlled affiliates upon the termination of the Executive’s employment for any reason. The Executive shall execute any documents in reasonable form as
may be reasonably requested by the Company to confirm or effectuate any such resignations. 
 4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company
shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary and Target Incentive Compensation earned through the Date of Termination, unpaid expense reimbursements (subject to, and
in accordance with, Section 2(c) of this Agreement); (ii) any accrued but unused vacation time (it being understood that, as of the Effective Date, the Company does not accrue vacation time), and (iii) any vested benefits the Executive may
have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued
Benefit”). For the avoidance of doubt, the Executive’s right to indemnification by the Company and coverage under any applicable directors’ and officers’ liability or other third party insurance policy as provided herein
shall continue following any such termination of employment. 
 (b) Termination by the Company without Cause or by the
Executive for Good Reason. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates the Executive’s employment for Good Reason as provided
in Section 3(e), in either case outside of the Change in Control Period, then the Company shall pay the Executive the Executive’s Accrued Benefit. In addition, subject to the Executive signing, not revoking and complying with a separation
agreement in the form and manner provided by the Company no later than five (5) days following the Date of Termination, containing a general release of claims in favor of the Company and related persons and entities, a reaffirmation of the
Executive’s obligations under the Executive’s Restrictive Covenant Agreement, confidentiality of agreement, return of property, reasonable litigation cooperation at the Company’s cost, mutual
non-disparagement, a post-employment non-competition provision equal or less in duration than the Executive’s severance period, and a seven (7) business day
revocation period (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming irrevocable, all within all within the time period required in the Separation Agreement and Release but in no event
later than 60 days after the Date of Termination: 
 (i) the Company shall pay the Executive an amount equal to the
Executive’s Base Salary (the “Severance Amount”). Notwithstanding the foregoing, if the Executive materially breaches any of the provisions contained in Section 7 of this Agreement or in the Restrictive Covenant Agreement,
all payments of the Severance Amount may be terminated by the Company without affecting the other provisions of the Separation Agreement and Release; 

(ii) the Company shall pay the Executive an amount in cash equal to a pro rata portion (based on the days of the applicable
fiscal year prior to and including the Date of Termination) of the Executive’s Target Incentive Compensation, which payment shall be made in a single lump sum within 60 days after the Date of Termination. 

 (iii) subject to the Executive’s copayment of premium amounts at the
applicable active employees’ rate and the Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health
plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until
the earliest: (i) the twelve-month anniversary of the Date of Termination; (ii) the Executive’s eligibility for group health coverage through other employment; or (iii) the end of the Executive’s eligibility under COBRA for
continuation coverage for health care. Notwithstanding the foregoing, if the Company determines at any time that its payments pursuant to this paragraph may be taxable income to the Executive, it may convert such payments to payroll payments
directly to the Executive on the Company’s regular payroll dates, which shall be subject to tax-related deductions and withholdings; and 

(iv) The amounts payable under Section 4(b) (except Section 4(b)(ii)), to the extent taxable, shall be paid out in
substantially equal installments in accordance with the Company’s payroll practice over twelve months, commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period
begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as “non-qualified deferred compensation” within the meaning of Section 409A of
the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall
include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for
purposes of Treasury Regulation Section 1.409A-2(b)(2)). 
 5. Change in Control
Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company.
These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to the Executive’s assigned duties and the Executive’s objectivity during the pendency and after the occurrence of any
such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment by the Company without Cause or by the Executive for Good Reason,
if such termination of employment occurs upon, immediately prior to, in connection with or within 18 months after the occurrence of the first event constituting a Change in Control (such period, the “Change in Control Period”).
These provisions shall terminate and be of no further force or effect beginning 18 months after the consummation of a Change in Control. 

(a) Change in Control. If during the Change in Control Period the Executive’s employment is terminated by the
Company without Cause as provided in Section 3(d) or the Executive terminates the Executive’s employment for Good Reason as provided in Section 3(e), then, in addition to paying the Executive the Accrued Benefit, and subject to the
signing, non-revocation and compliance with the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming irrevocable, all within the time period required in the
Separation Agreement and Release but in no event later than 60 days after the Date of Termination: 
 (i) the Company shall
pay the Executive a lump sum in cash in an amount equal to one and one-half (1.5) times the sum of (A) the Executive’s then current Base Salary (or the Executive’s Base Salary in effect
immediately prior to the Change in Control, if higher) plus (B) the Executive’s Target Incentive Compensation (or the Executive’s Target Incentive Compensation in effect immediately prior to the Change in Control, if higher) (the
“Change in Control Payment”); and 
 (ii) notwithstanding anything to the contrary in any applicable option
agreement or other stock-based award agreement or the Company’s equity plan, all stock options and other stock-based awards (collectively, the “Equity Awards”) held by the Executive shall immediately accelerate and become fully
exercisable or nonforfeitable (with any Equity Awards subject to performance-based vesting 

 
conditions becoming vested based on the attainment of the greater of (A) target level performance or (B) actual performance as of the Date of Termination) as of the Accelerated Vesting
Date; provided that any termination or forfeiture of the unvested portion of such Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement under any applicable option agreement, other stock-based award
agreement or the Company’s equity plan will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement
and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, (i) no additional vesting of the Equity Awards shall occur during the period between the Executive’s Date of Termination and the
Accelerated Vesting Date and (ii) to the extent the parties to a Sale Event (as defined in the Equity Documents) do not provide for the assumption, continuation or substitution of Equity Awards, upon the effective time of the Sale Event, such
Equity Awards shall immediately accelerate and become fully exercisable or nonforfeitable (with any Equity Awards subject to performance-based vesting conditions becoming vested based on the attainment of the greater of (A) target level
performance or (B) actual performance as of the date of the Sale Event); and 
 (iii) subject to the Executive’s
copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider, the COBRA provider or the Executive a
monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest: (i) the 18-month anniversary of the Date of Termination; (ii) the Executive’s eligibility for group health coverage through other employment; or (iii) the end of the Executive’s eligibility under COBRA
for continuation coverage for health care. Notwithstanding the foregoing, if the Company determines at any time that its payments pursuant to this paragraph may be taxable income to the Executive, it may convert such payments to payroll payments
directly to the Executive on the Company’s regular payroll dates, which shall be subject to tax-related deductions and withholdings. 

(iv) The amounts payable under this Section 5(a), to the extent taxable, shall be paid or commence to be paid within 60
days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period. 
 (b) Additional Limitation. 

(i) Notwithstanding anything in this Agreement to the contrary, if the amount of any compensation, payment or distribution by
the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code
of 1986, as amended (the “Code”) and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall
be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction
shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be
reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:
(1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash
forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1,
Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1,
Q&A-24(b) or (c). 

 (ii) For purposes of this Section 5(b), the “After Tax
Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of
determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state
and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes that could be obtained from deduction of such state and local taxes. 

(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5(b)(i)
shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date
of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive, absent manifest error or omission. The
costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by the Company. 

(c) Definitions. For purposes of this Section 5, the term “Change in Control” shall have the
following meaning: 
 (i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended (the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its
subsidiaries), together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such
term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company’s then outstanding
securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the Company); or 

(ii) the date on which a majority of the members of the Board is replaced during any
12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or 

(iii) the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company,
immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly,
shares representing in the aggregate more than fifty percent (50%) of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer
(in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. 

Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as
the result of an acquisition of securities by the Company that, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to fifty percent (50%) or
more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns fifty percent (50%) or more of the
combined voting power of all of the then outstanding Voting Securities, then a Change in Control shall be deemed to have occurred for purposes of the foregoing clause (i). 

 6. Section 409A. 

(a) Notwithstanding anything in this Agreement to the contrary, if at the time of the Executive’s separation from service
within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the
Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the twenty percent (20%) additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a
catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the
installments shall be payable in accordance with their original schedule. 
 (b) All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). This right to reimbursement or in-kind benefits is not subject to liquidation or exchange for
another benefit. 
 (c) To the extent that any payment or benefit described in this Agreement constitutes “nonqualified
deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the
Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A1(h).
Notwithstanding anything in this Agreement to the contrary, to the extent any payment that the Executive becomes entitled to under Section 5(a)(i) constitutes “non-qualified deferred
compensation” under Section 409A of the Code and is not otherwise exempt from Section 409A of the Code, the definition of “Change in Control” for purposes of such payment must also constitute a “change in control
event,” as defined in Treasury Regulation Section 1.409A-3(i)(5). 
 (d)
The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision
shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation
Section 1.409A2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to
preserve the payments and benefits provided hereunder without additional cost to either party. 
 (e) The Company makes no
representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an
exemption from, or the conditions of, such Section. 
 7. Confidential Information,
Non-competition and Cooperation. 
 (a) As a condition of employment, the
Executive is required to enter into the Employee Confidentiality, Non-Solicitation and Assignment Agreement, attached hereto as Exhibit A (the “Restrictive Covenants Agreement”). For purposes
of this Agreement, the obligations in this Section 7, 

 
those that arise in the Restrictive Covenants Agreement, the post-employment non-competition obligation to be contained in any Separation Agreement and
Release as may be entered into by and between the Company and Executive, and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing
Obligations.” 
 (b) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is
not bound by the terms of any agreement with any previous employer or other party that restricts in any way the Executive’s use or disclosure of information or the Executive’s engagement in any business in a manner that would interfere
with or inhibit the Executive’s ability to perform the Executive’s duties to the Company. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and
the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not
disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party. 

(c) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall
reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while the
Executive was employed by the Company. The Executive’s cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on
behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state or local
regulatory authority that relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable
out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 7(c). 

(d) Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company that might
result from any breach by the Executive of the Continuing Obligations and that, in any event, money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to
breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any
actual damage to the Company. 
 (e) Protected Disclosures and Other Protected Actions. Nothing in this Agreement
shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a “Government Agency”) concerning any act or omission that the Executive reasonably
believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation. In addition, nothing contained
in this Agreement limits the Executive’s ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including the Executive’s ability to
provide documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal
or state trade secret law or under this Agreement or the Restrictive Covenant Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or
indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. 

 8. Arbitration of Disputes. 

(a) Arbitration Generally. Any controversy or claim arising out of or relating to this Agreement or the breach thereof
or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national origin, sex,
gender, age, disability, sexual orientation, or any other protected class under applicable law, including without limitation Massachusetts General Laws Chapter 151B) shall, to the fullest extent permitted by law, be settled by arbitration in any
forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in Boston, Massachusetts in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures
applicable to the selection of arbitrators. The Executive understands that the Executive may only bring such claims in the Executive’s individual capacity and not as a plaintiff or class member in any purported class proceeding or any purported
representative proceeding. The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other. Judgment upon the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court
action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants Agreement;
provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 8. 

(b) Arbitration Fees and Costs. The Executive shall be required to pay an arbitration fee to initiate any arbitration
equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator. However, to the extent permissible under the law, and following the arbitrator’s ruling
on the matter, the arbitrator may rule that the arbitrator’s fees and costs be distributed in an alternative manner. Each party shall pay its own costs and attorneys’ fees, if any. If, however, any party prevails on a statutory or
contractual claim that affords the prevailing party attorneys’ fees (including pursuant to this Agreement), the arbitrator may award attorneys’ fees to the prevailing party to the extent permitted by law. 

9. Consent to Jurisdiction. To the extent that any court action is permitted consistent with or to enforce Section 8 of this
Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the
Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal
jurisdiction or service of process. 
 10. Indemnification. The Company and the Executive hereby agree to execute the Company’s
standard indemnification agreement for senior executives. 
 11. Integration. This Agreement constitutes the entire agreement between
the parties with respect to compensation, severance pay, benefits and accelerated vesting and supersedes in all respects all prior agreements between the parties concerning the subject matter hereof, including without limitation the Prior Agreement
and any severance agreements, provided that the Restrictive Covenant Agreement, the Equity Documents, any indemnification agreement, and any other agreement relating to confidentiality, non-competition, non-solicitation or assignment of inventions shall not be superseded by this Agreement and the Executive acknowledges and agrees that any such agreements remains in full force and effect. 

12. Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts
required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or
for any deduction or withholding from any payment or benefit. 

 13. Enforceability. If any portion or provision of this Agreement (including, without
limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or
provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law. 
 14. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 15. Waiver. No waiver of any
provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement,
shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
 16.
Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified
mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. 

17. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized
representative of the Company. 
 18. Effect on Other Plans and Agreements. Nothing in this Agreement shall be construed to limit the
rights of the Executive under the Company’s benefit plans, programs or policies except as otherwise provided in Section 7 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay
plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such agreement and this Agreement, the terms of this Agreement shall govern and the Executive may
receive payment under this Agreement only and not both. Further, Section 4 and Section 5 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to Section 4 and
Section 5 of this Agreement. 
 19. Governing Law. This is a Massachusetts contract and shall be construed under and be governed
in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance
with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. 
 20. Assignment.
Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its
rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate
with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that if the purchaser in any transaction involving the transfer of all or substantially all of the Company’s assets
assumes this Agreement and the Executive accepts a position with the purchaser that is equivalent or better to the Executive’s position immediately preceding such transaction, then the Executive shall not be entitled to any Severance Amount
pursuant to Section 4 or any Change in Control Payment pursuant to Section 5. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s
respective successors, executors, administrators, heirs and permitted assigns. 
 21. Counterparts. This Agreement may be executed in
any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

 22. Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be
considered as including the feminine gender unless the context clearly indicates otherwise. 
 [Signature Page Follows.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective
Date. 
  

			
	C4 THERAPEUTICS, INC.

 
			
		
	By:	 	 /s/ Marc Cohen

 
			
	Name:	 	Marc Cohen
	Title:	 	CEO
	
	EXECUTIVE
	
	 /s/ Andrew Hirsch

	Andrew Hirsch

 Exhibit A 

Restrictive Covenant Agreement 

Omitted.EX-10.9

 Exhibit 10.9 

C4 THERAPEUTICS, INC. 

CONSULTATION AGREEMENT 

Consultation Agreement (“Agreement”), effective as of March 31, 2020 (the “Effective Date”), between C4
Therapeutics, Inc., a Delaware corporation, having a place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472 (“C4T” or “Company”), and MBJC Associates, LLC having an address at 832 Schirra Drive,
Oradell, New Jersey 07649 (“Consultant”). 
 W I T N E S S E T H: 

WHEREAS, C4T desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide consulting services
to C4T, all as hereinafter provided in this Agreement; 
 NOW, THEREFORE, in consideration of the premises and mutual agreement hereinafter
set forth, effective as of the Effective Date, C4T and Consultant hereby agree as follows: 
 1. Consultation. Consultant hereby agrees to
render the services described on Schedule A attached hereto and incorporated herein by reference, as well as such other duties which may be requested by C4T from time to time and mutually agreed upon by C4T and Consultant and which are
necessary and reasonably related to the successful completion of the services described on Schedule A (together, the “Services”). Consultant shall report to Marc Cohen, Chairman and Chief Executive Officer. 

2. Term. This Agreement shall commence on the Effective Date and shall continue for an initial term of one year (12 months). Thereafter, this
Agreement shall automatically renew for 30-day periods unless terminated pursuant to the following sentence. Notwithstanding the foregoing, it is understood and agreed either party may terminate this Agreement
at any time by providing thirty (30) days prior written notice to the other party. The actual length of Consultant’s service hereunder is the “Term.” 

3. Consulting Duties. 
  

	(a)	 During the Term, Consultant shall render to C4T or to C4T’s designee the Services, which Services shall be
rendered by Consultant as described on Schedule A attached hereto. Services shall be performed on behalf of Consultant by William McKee. 

  

	(b)	 The Services shall be performed by Consultant and may not be assigned, subcontracted or otherwise delegated
without the prior written consent of C4T. 

  

	(c)	 Consultant will be expected to provide the Services during the Term for an amount of time as mutually agreed
with C4T, as reviewed and approved by Mr. Cohen from time to time. Consultant agrees to furnish C4T with written reports with respect to Consultant’s provision of the Services if and when requested by C4T. 

4. Compensation. 
  

	(a)	 In consideration of Consultant’s performance of the Services, during the Term, Consultant shall be
compensated as set forth on Schedule A attached hereto. Consultant will invoice C4T for services on a monthly basis. C4T will pay the invoices within 30 days of an undisputed invoice. Invoices should be sent to ap@c4therapeutics.com.

	(b)	 C4T shall reimburse Consultant for reasonable
out-of-pocket expenses incurred in the performance of its duties hereunder as requested by C4T upon presentation of reasonably detailed receipts. Domestic (North
American) travel will be in coach class; with the prior written approval of C4T, all travel outside of North America will be business class.    For all
out-of-pocket business expenses in excess of five hundred dollars ($500) Consultant agrees to obtain C4T’s prior written consent prior to incurring such expenses.

 In the event this Agreement is terminated by Consultant or by C4T for any reason, no compensation of any kind shall be
payable or issuable to Consultant after the effective date of such termination, other than a liability or obligation of either party which accrued prior to such termination or other than as expressly provided in Schedule A. C4T shall have no
obligation to make any payment pursuant to this Agreement unless Consultant is in compliance with all its covenants and agreements. 
 5. Independent
Contractor Status; No Employment Created. Consultant acknowledges that the relationship of Consultant to C4T is at all times that of an independent contractor. This Agreement does not constitute, and shall not be construed as constituting, an
employment relationship between C4T and any persons or as an undertaking by C4T to hire Consultant or any person as an employee of C4T. Consultant will perform the Services free of the direction and control of C4T, but consistent with the objectives
it sets, and will bear the benefit/risk of any profit or loss from rendering the Services. Consultant shall not be deemed an agent for any purpose and shall have no authority to bind C4T. Consultant will not be considered an employee of C4T for any
purpose, including without limitation, any C4T employment policy or any employment benefit plan, and will not be entitled to any benefits under any such policy or benefit plan (including without limitation workers compensation insurance). C4T will
record payments to Consultant on an Internal Revenue Service Form 1099, and will not withhold any federal, state or local employment taxes on Consultant’s behalf. Consultant will be solely responsible for the payment of all federal, state and
local taxes and contributions imposed or required on income, and for all unemployment insurance, social security contributions and any other payment, including workers compensation. 

6. Protected Information. 
  

	(a)	 Consultant will at all times, both during the period while Consultant is performing the Services for C4T and
after the termination of Consultant’s provision of the Services to C4T for any reason or for no reason, maintain in confidence and will not, without the prior written consent of C4T, use, except in the course of performance of Consultant’s
duties for C4T or by court order, disclose or give to others any Confidential Information (as defined below). In the event Consultant is questioned by anyone not employed by C4T or by an employee of or a consultant to C4T not authorized to receive
Confidential Information, in regard to any Confidential Information, or concerning any fact or circumstance relating thereto, Consultant will promptly notify C4T. Upon the termination of Consultant’s provision of the Services to C4T for any
reason, or if C4T otherwise requests, (i) Consultant will return to C4T all tangible Confidential Information and copies thereof (regardless of how such Confidential Information or copies are maintained) and (ii) Consultant will deliver to
C4T any property of C4T which may be in Consultant’s possession, including products, materials, memoranda, notes, records, reports, or other documents or photocopies of the same. 

 

	(b)	 For purposes of this Agreement, “Confidential Information” means confidential and proprietary
information of C4T, whether in written, oral, electronic or other form, including but not limited to, information and facts concerning business plans, customers, future customers, suppliers, licensors, licensees, partners, investors, affiliates or
others, training methods and materials, financial information, sales prospects, client lists, inventions, or any other scientific, technical or trade secrets of C4T or of any third party provided to Consultant or C4T under a condition of
confidentiality, provided that Confidential Information will not include information that is in the public domain other than through any fault or act by Consultant. The term “trade secrets,” as used in this Agreement, will be given its
broadest possible interpretation under the law and will include, without limitation, anything tangible or intangible or electronically kept or stored, which constitutes, represents, evidences or records or any secret scientific, technical,
merchandising, production or management information, or any design, process, procedure, formula, invention, improvement or other confidential or proprietary information or documents. 

	(c)	 The terms of this Section 6 are in addition to, and not in lieu of, any statutory or other contractual or
legal obligation that Consultant may have relating to the protection of C4T’s Confidential Information. 

 7. Trade Secrets.
Consultant acknowledges, and shall inform its employees and representatives of, the following notice required by the Defend Trade Secrets Act: An individual will not be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law. Similarly, an individual will not
be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An
individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to that individual’s attorney and use the trade secret information in the court proceeding, if the individual
files any document containing the trade secret under seal; and does not disclose the trade secret, except pursuant to court order. 
 8. Ownership of
Ideas, Copyrights and Patents. 
  

	(a)	 Assignment of Rights/Property of C4T. All ideas, discoveries, creations, improvements and inventions ,
whether patentable, copyrightable or not, which Consultant may conceive, reduce to practice or develop as a result of performing the Services for C4T (alone or in conjunction with another or others) and whether at the request or upon the suggestion
of C4T or otherwise (collectively the “Inventions”), are the sole and exclusive property of C4T and the Confidential Information of C4T, and Consultant will not disclose any of the Inventions without the prior written consent of C4T or its
designee. Without limiting the foregoing, Consultant also acknowledges that all original works of authorship which are made by Consultant (solely or jointly with others) within the scope of the Services or which relate to the business of C4T or a
C4T affiliate and which are protectable by copyright are “works made for hire” pursuant to the United States Copyright Act (17 U.S.C. Section 101). Consultant hereby assigns to C4T or its designee all of his right, title and interest
in and to all of the foregoing. Consultant further represents that, to the best of his knowledge and belief, none of the Inventions will violate or infringe upon any right, patent, copyright, trademark or right of privacy. Consultant agrees to
promptly notify C4T of any Inventions conceived, reduced to practice or developed as a result of performing the Services for C4T. Consultant agrees to make and maintain adequate and current written records, in a form specified by C4T, of all
Inventions assigned or to be assigned to C4T pursuant to this Agreement and, upon termination of Consultant’s relationship with C4T, to deliver to C4T such records, including without limitation any materials recorded on any computer or any
machine readable medium. 

  

	(b)	 Cooperation. At any time during or after the period during which Consultant is performing the Services
for C4T, Consultant will fully cooperate with C4T and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect C4T’s rights in and to any of such Inventions, including, but not
limited to, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that C4T will bear the expense of such
proceedings, and that any patent or other legal right so issued to Consultant will be assigned by Consultant to C4T or its designee without charge by Consultant. 

	(c)	 Licensing and Use of Innovations. With respect to any Inventions, and work of any similar nature,
whenever created, which Consultant has not prepared or originated in the performance of the Services, but which Consultant provides to C4T or incorporates in any C4T product or system, Consultant hereby grants to C4T a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish, translate, reproduce, deliver,
perform, dispose of, and to authorize others so to do, all such Inventions. Consultant will not include in any Inventions delivered to C4T or use on its behalf, without the prior written approval of C4T, any material which is or will be patented,
copyrighted or trademarked by Consultant unless Consultant provides C4T with the written permission of the holder of any patent, copyright or trademark owner for C4T to use such material in a manner consistent with C4T’s then-current policy.
Consultant will not knowingly include in any Inventions delivered to C4T or use on its behalf, any material which is patented, the subject of a patent application, copyrighted or trademarked by a third party unless Consultant informs C4T at the time
of disclosure or at the time Consultant becomes aware of such material. 

  

	(d)	 Prior Inventions. Listed on Exhibit A to this Agreement are any and all Inventions in which
Consultant claims or intends to claim any right, title and interest, including, without limitation, patent, copyright and trademark interests, which to the best of Consultant’s knowledge will be or may be delivered to C4T in the course of
performing the Services, or incorporated into any C4T product or system. Consultant acknowledges that her or his obligation to disclose such information is ongoing during the period that Consultant provides the Services. 

9. Prohibited Conduct 
  

	(a)	 Certain Acknowledgements and Agreements. 

 

	 	(i)	 C4T and Consultant have discussed, and Consultant recognizes and acknowledges the competitive and proprietary
aspects of C4T’s business. 

  

	 	(ii)	 Consultant acknowledges and agrees that a business will be deemed competitive with C4T (a “Competitive
Business”) if it engages in a line of business in which it researches, develops or commercializes any products or product candidates in C4T’s Field of Interest (as hereinafter defined). The phrase, C4T’s “Field of
Interest,” means research, development and commercialization activities relating to bifunctional molecules that induce targeted protein degradation, or such other areas of research, development and commercialization as the C4T may be
engaged in during the term of this Agreement. 

  

	 	(iii)	 Consultant further acknowledges that, while Consultant is providing the Services hereunder, C4T will furnish,
disclose or make available to Consultant Confidential Information related to C4T’s business and that C4T may provide Consultant with unique and specialized training. Consultant also acknowledges that such Confidential Information and such
training have been developed and will be developed by C4T through the expenditure by C4T of substantial time, effort and money and that all such Confidential Information and training could be used by Consultant to compete with C4T.

	(b)	 Non-Competition;
Non-Solicitation. Without the prior written consent of C4T, neither Consultant nor any of its officers, owners or employees will: 

 

	 	(i)	 Following the termination of Consultant’s provision of the Services to C4T for any reason or for no
reason, (1) utilize C4T’s Confidential Information for any reason other than performing the Services hereunder; or 

  

	 	(ii)	 During the period in which Consultant performs the Services for or at the request C4T and for a period of two
(2) years following the termination of Consultant’s provision of the Services to C4T for any reason or for no reason either individually or on behalf of or through any third party, directly or indirectly, (A) solicit, entice or
persuade or attempt to solicit, entice or persuade any employee of or consultant to C4T to terminate her or his relationship with C4T or any such parent, subsidiary or affiliate for any reason, or (B) employ, cause to be employed, or solicit
the employment or engagement of any employee of or consultant to C4T while any such person is providing services to C4T or within six months after any such person ceases providing services to C4T; or 

 

	 	(iii)	 During the period in which Consultant performs the Services for or at the request of C4T and for a period of
two (2) years following the termination of Consultant’s provision of the Services to C4T for any reason or for no reason either individually or on behalf of or through any third party, directly or indirectly, interfere, with or attempt to
interfere with, the relations between C4T and any vendor, supplier or strategic partner to C4T. 

 10. Survival of Provisions. The
provisions of Sections 6, 8, 9 and 12 hereof and any other sections that by their nature are intended to survive termination, shall survive the termination or expiration of this Agreement, irrespective of the reason therefore. 

11. No Conflicts. Except as set forth in Exhibit B to this Agreement, Consultant hereby represents and warrants that
(i) Consultant has no commitments or obligations inconsistent with this Agreement; and (ii) the performance by Consultant of the Services within the Field of Interest do not as of the Effective Date and shall not at any time during the
Term conflict with, breach any covenants or agreements regarding, or otherwise overlap, any field in which Consultant is providing professional services. Consultant hereby agrees to indemnify and hold C4T harmless against any claim based upon
circumstances alleged to be inconsistent with such representations and/or warranties. 
 12. Indemnification.    The Company
agrees to indemnify and hold harmless Consultant and William McKee from and against, and reimburse Consultant and William McKee with respect to, any and all losses, claims, damages, liabilities, penalties, judgments, settlements, obligations and
expenses, including interest, penalties, and reasonable attorneys’ fees incurred by Consultant and William McKee in connection with any third party or governmental action, proceeding, investigation or suit, or threatened suit (each, an
“Action”) in any way arising out of or relating to Consultant’s performance of the Services under this Agreement, unless due to the gross negligence or willful misconduct of Consultant provided however, that in connection with claims
of gross negligence or willful misconduct, the Company will continue to indemnify and hold harmless the Consultant and William McKee including but not limited to the payment of attorney’s fees and costs until a final non-appealable adjudication of such conduct . If any such Action is commenced to which Consultant and William McKee proposes to demand indemnification hereunder, Consultant and William McKee will notify the Company
with reasonable promptness; provided, however, that any failure by Consultant and William McKee to notify the Company will not relieve the Company from its obligations hereunder except to the extent the Company is actually prejudiced by the failure
of Consultant to provide prompt notice. The Company shall control the defense of any such Action, at its expense; provided that no such Action shall be settled in a manner that adversely impacts Consultant and William McKee without the written
consent of the Consultant, not to be unreasonably withheld..” 

 13. Injunctive Relief; Severability; Blue Pencil. Consultant hereby expressly acknowledges that any
breach or threatened breach of any of the terms and/or conditions set forth in Sections 6, 8 and 9 of this Agreement may result in substantial, continuing and irreparable injury to C4T. Therefore, Consultant hereby agrees that, in addition to any
other remedy that may be available to C4T, C4T shall be entitled to seek injunctive or other equitable relief by a court of appropriate jurisdiction in the event of any breach or threatened breach of the terms of Sections 6, 8 and 9 of this
Agreement. In addition, the parties intend Sections 6, 8 and 9 of this Agreement to be enforced as written. However, (i) if any provision of such sections is to any extent declared illegal or unenforceable by a duly authorized court having
jurisdiction, then the remainder of such sections, or the application of such provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected thereby, and each provision of such sections will
be valid and enforceable to the fullest extent permitted by law; and (ii) if any provision of such sections, or part thereof, is held to be unenforceable because of the duration of such provision or the geographic area covered thereby, the
court making such determination will have the power to reduce the duration and/or geographic area of such provision, and/or to delete specific words and phrases (“blue-penciling”), and in its reduced or blue-penciled form such provision
will then be enforceable and will be enforced. 
 14. Assignability and Binding Effect. Neither this Agreement nor any interest shall be
assignable by either party unless such assignment is mutually agreed to in writing by the parties hereto; provided, however, that C4T may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all
of C4T’s business or that aspect of C4T’s business in which Consultant is principally involved without obtaining the agreement of Consultant. 

15. Rights of Publicity. Neither party shall have the right to use the other party’s name in any publications or publicity materials without
obtaining the prior written consent of the other party. 
 16. Headings. The section headings contained herein are included solely for
convenience of reference and shall not control or affect the meaning or interpretation of any of the provisions of this Agreement. 
 17.
Notices. Any notices or other communications hereunder by either party shall be in writing and shall be deemed to have been duly given if delivered personally to the other party or sent by registered or certified mail, return receipt
requested, or via reputable courier to the other party at the following addresses: 
  

			
	 If to C4T:
	  	C4 Therapeutics, Inc.
		  	490Arsenal Way,Suite 200
		  	Watertown, MA 02472
		  	Tel: 617-588-6123
		  	E-mail: contracts@c4therapeutics.com
		  	Attention: Contracts Administrator
		
	 If to Consultant:
	  	William McKee
		  	832 Schirra Drive
		  	Oradell, New Jersey 07649
		  	E-mail: wtmckee@optonline.net

 or at such other address as such other party may designate in conformity with the foregoing. 

 18. Entire Agreement; Modification. This document embodies the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and will supersede all prior and contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto. No statement, representation,
warranty, covenant or agreement of any kind not set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Agreement. This Agreement shall not be amended or modified in any manner
except by an instrument signed by each of the parties hereto, which document shall make specific reference to this Agreement and shall express the plan or intention to modify same. 

 
 19. Governing Law; Jurisdiction; Venue; Waiver of Jury Trial. This Agreement and
the rights and obligations of the parties hereunder will be construed in accordance with and governed by the law of The Commonwealth of Massachusetts, without giving effect to conflict of law principles thereof, and specifically excluding any
conflict or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. Any legal action or proceeding with respect to this Agreement shall be brought in
the courts of The Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property,
generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF C4T AND CONSULTANT WAIVE ANY RIGHT
TO A JURY TRIAL THEREOF. 
 20. Interpretation. The parties hereto acknowledge and agree that (i) the rule of construction to the effect that
any ambiguities are resolved against the drafting party, and (ii) the terms and provisions of this Agreement, shall be construed fairly as to all parties hereto and not in favor of or against a party, regardless of which party was generally
responsible for the preparation of this Agreement. 
 21. Counterparts. This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 22. Insurance. Company agrees that William
McKee is or will be added as a named insured or an additional insured to the Company’s Director and Officers insurance policy and any other insurance policy covering services provided by the Consultant under this agreement. The Company also
agrees to provide the Consultant with a Certificate of Insurance showing that William T McKee is a named insured under the policy. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, this Agreement is executed under seal by both parties. 

 

			
	C4 THERAPEUTICS, INC.
		
	By:	 	 /s/ Marc Cohen

	Name:	 	Marc Cohen
	Title:	 	Chief Executive Officer

  

			
	CONSULTANT:
		
	By:	 	 /s/ William McKee

	Name:	 	MBJC Associates, LLC
		 	William McKee

 Schedule A 

Description of Services 
  

	1.	 Contact: Consultant’s principal contact at C4 Therapeutics: 

  Name: Marc Cohen 

  Title:   Chairman and Chief Executive Officer 
  

	2.	 Summary of Services: Consultant will render to the C4T the following Consulting Services as Chief
Financial Officer: 

  

	 	(i)	 Supervision of the company’s current accounting and finance staff 

 

	 	(ii)	 Review of periodic financial reports 

 

	 	(iii)	 Review of existing shareholder agreements 

 

	 	(iv)	 Review of documents supporting current financing round 

 

	 	(v)	 Work with Company’s existing accounting firm and legal counsel in the preparation and review of materials
needed to support the current financing round. 

  

	 	(vi)	 Meet with Company’s board of directors as needed 

 

	 	(vii)	 Assist CEO and Executive Chairman of the Board in hiring full time CFO and provide any transition, as needed

  

	 	(viii)	 Attend Senior Leadership Meetings as CFO and other meetings as needed 

 

	 	(ix)	 Strategic planning for the finance department for current and future C4T success 

 

	3.	 Compensation: 

 

	 	a.	 In consideration of Consultant’s performance of the Services during the Term, C4T shall pay Consultant a
consulting fee of $350 per hour, not to exceed $50,000 per month after June 30, 2020, as per the payment terms outlined in Section 4(a) of this Agreement. 

 

	 	b.	 C4T shall reimburse Consultant for all reasonable business expenses incurred in the performance of the
Services as per Section 4(b) of this Agreement. 

  

	 	c.	 Consultant shall be eligible to receive a discretionary cash bonus if the Company successfully completes
an initial public offering during the Term. The amount of any such bonus shall be determined by the Board (including its Chairman) in its sole (but good faith) discretion, and the Parties agree that any such bonus shall not exceed 0.1% (one tenth of
one percent) of the Company’s Pre-Money IPO Valuation. “Pre-Money IPO Valuation” means (i) the Company’s public offering price per share
in the Company’s initial public offering multiplied by (ii) the sum of the Company’s issued and outstanding shares of stock and the Company’s granted and outstanding options under its Stock Option and Grant Plan (as defined
below), as such shares and options are measured as of immediately prior to the consummation of the Company’s initial public offering. 

	4.	 Stock Options: All references to Consultant hereunder include William McKee. Subject to the
approval of the Company’s Board of Directors, William McKee will be issued an option to purchase 2,499,028 shares of Company common stock (the “Shares”) that will vest in sixty monthly installments, provided that
Consultant remains in a continuous service relationship with the Company on each applicable vesting date, and subject in all respects to the terms and conditions of the C4 Therapeutics, Inc. 2015 Stock Option and Grant Plan, as amended (the
“Stock Option and Grant Plan”) and the applicable stock option agreement (collectively, the “Equity Documents”), at an exercise price equal to the fair market value of the Company’s common stock on the date of
grant (the “Option Grant”). 

 Notwithstanding anything in the Equity Documents to the contrary, in the
event that Consultant’s service relationship is terminated by the Company without Cause during the initial, twelve-month Term of this Agreement, then the Shares with respect to such initial term shall be deemed vested and exercisable in full
upon such termination. 
 Notwithstanding anything in the Equity Documents to the contrary, in the case of a Sale Event (as defined in the
Equity Documents), the Option Grant shall be treated as provided in Schedule A. Section 3(c) of the Stock Option and Grant Plan; provided, however, that (X) if the Option Grant is not assumed or continued by the Company or its successor
entity in the sole discretion of the parties to a Sale Event, then the Shares with respect to the then-outstanding Term of this Agreement shall be deemed vested and exercisable in full immediately prior to the
closing of such Sale Event if and only if Consultant continues to have a service relationship with the Company at the time of such closing, and otherwise (Y) if the Option Grant or the Shares are assumed or continued by the Company or its
successor entity in the sole discretion of the parties to a Sale Event and thereafter remain in effect following such Sale Event, then the Shares with respect to the then-outstanding Term of this Agreement
shall be deemed vested in full upon the date on which the Optionee’s service relationship with the Company and its subsidiaries or successor entity terminates if (A) such termination occurs by the Company without Cause and (B) such
termination is during the then-outstanding term of this Agreement. 
 If the Consultant’s
service relationship is terminated for any reason, other than a termination by the Company for Cause (as defined below), the vested Shares shall remain exercisable for (A) a period of 18 months following the later of (x) the last day of
Consultant’s service relationship with the Company (the “Service End Date”) or (y) the end of the initial term of this Agreement or (B) until the 10-year anniversary of the grant date
of the Option Grant, whichever occurs earlier. In the unlikely event the Consultant’s service relationship is terminated by the Company for Cause, the exercise period (if any) shall be governed by the Equity Documents. To the extent any portion
of the Option Grant is unvested as of the Service End Date, the Shares subject to such unvested portion shall expire and become null and void as of such Date. 

For purposes of the Agreement, “Cause” shall mean, as determined by the Company in good faith: Consultant’s dishonest
statements or acts with respect to the Company or any affiliate of the Company; (ii) Consultant’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;
(iii) Consultant’s failure to perform Consultant’s assigned duties and responsibilities (including, but not 

 
limited to Consultant’s failure to meet those certain travel obligations set forth on Schedule A attached hereto) to the reasonable satisfaction of the Board, which failure continues for
more than 30 days after written notice given to Consultant by the Company detailing such failure to perform; (iv) Consultant’s gross negligence or willful misconduct with respect to the Company or any affiliate of the Company; or
(v) Consultant’s material violation of any provision of any agreement(s) between Consultant and the Company relating to non-solicitation, nondisclosure and/or assignment of inventions. 

 Exhibit A 

(Prior Inventions) 

 Exhibit B 

(Conflicts) 
 William McKee serves
on the board of directors of 2 public companies, neither of which are in 
 the Field of Interest

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]